Huahui Health, BeOne Medicines Partner to Advance Oncology Drug HH160

Huahui Health has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines, a global oncology company, is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide.

HH160 simultaneously targets PD-1, CTLA-4, and VEGF-A, three clinically validated targets in cancer immunotherapy and anti-angiogenesis. Through its “three-in-one” synergistic mechanism of action, HH160 is expected to enhance therapeutic efficacy, achieve tumor-specific drug distribution, and reduce treatment-related adverse effects.

Pursuant to the agreement, BeOne Medicines will pay Huahui Health an upfront payment of $20 million. Upon exercise of the option by BeOne Medicines, Huahui Health will be entitled to receive an additional $100 million option exercise payment. Subject to the achievement of development, regulatory and sales milestones, Huahui Health is eligible to receive milestone payments of up to $1.9 billion in milestone payments, as well as tiered royalties on net sales. The parties have also agreed to maintain discussions regarding BeOne Medicines’ potential participation in Huahui Health’s future financing activities, with specific transaction terms and details to be negotiated separately.

Dr. Chen Bin, CEO of Huahui Health, said, “We are delighted to deepen our collaboration with BeOne Medicines to advance HH160, a novel trispecific antibody for cancer immunotherapy, and to bring innovative immuno-oncology treatments to patients worldwide as early as possible.”